PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside. [electronic resource]
Producer: 20190926Description: 2498-2506 p. digitalISSN:- 1097-0142
- Antineoplastic Agents, Immunological -- pharmacology
- Antineoplastic Combined Chemotherapy Protocols -- pharmacology
- BRCA1 Protein -- genetics
- BRCA2 Protein -- genetics
- Breast Neoplasms -- drug therapy
- Cell Survival -- drug effects
- Clinical Trials as Topic
- DNA Repair -- drug effects
- Drug Resistance, Neoplasm -- drug effects
- Female
- Humans
- Molecular Targeted Therapy -- methods
- Patient Selection
- Poly(ADP-ribose) Polymerase Inhibitors -- pharmacology
- Poly(ADP-ribose) Polymerases -- metabolism
- Synthetic Lethal Mutations
- Treatment Outcome
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Review
There are no comments on this title.
Log in to your account to post a comment.